Novo Holdings A/S reported 24 positions worth $1.67B for the quarter ended Jun 30, 2026, up 46.7% on the prior quarter. It opened 6 new positions, added to 2, trimmed 7 and exited 2. Its largest holding is Edgewise Therapeutics, Inc. at 13% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| COAG Hemab Therapeutics Holdings, Inc. | +4.18M | – | $153.55M | 9.18% |
| AVLN Avalyn Pharma Inc. | +3.88M | – | $127.84M | 7.64% |
| FND Floor & Decor Holdings, Inc. | +797.0K | – | $47.31M | 2.83% |
| ALMS Alumis Inc. | +1.10M | – | $30.95M | 1.85% |
| DYN Dyne Therapeutics, Inc. | +960.4K | – | $21.33M | 1.28% |
| INSM INSMED Inc | +120.7K | – | $12.87M | 0.769% |
| VRDN Viridian Therapeutics, Inc.\DE | +135.0K | +6.8% | $2.48M | 2.34% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | +64.1K | +2.9% | $488.27K | 1.02% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| BMRN Biomarin Pharmaceutical Inc | -660.0K | -100.0% | $37.28M | Exited |
| MIRM Mirum Pharmaceuticals, Inc. | -200.0K | -15.1% | $23.41M | 7.87% |
| AVBP ArriVent BioPharma, Inc. | -442.1K | -22.8% | $15.36M | 3.12% |
| ELVN Enliven Therapeutics, Inc. | -280.0K | -21.9% | $14.21M | 3.03% |
| PHVS Pharvaris N.V. | -350.0K | -20.0% | $12.10M | 2.89% |
| VALN Valneva SE | -1.06M | -100.0% | $6.61M | Exited |
| CLDX Celldex Therapeutics, Inc. | -175.0K | -14.6% | $6.51M | 2.28% |
| FDMT 4D Molecular Therapeutics, Inc. | -401.6K | -11.0% | $5.34M | 2.58% |
| PCVX Vaxcyte, Inc. | -60.0K | -7.0% | $3.49M | 2.78% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| COAG Hemab Therapeutics Holdings, Inc. | +4.18M | $153.55M | 9.18% |
| AVLN Avalyn Pharma Inc. | +3.88M | $127.84M | 7.64% |
| FND Floor & Decor Holdings, Inc. | +797.0K | $47.31M | 2.83% |
| ALMS Alumis Inc. | +1.10M | $30.95M | 1.85% |
| DYN Dyne Therapeutics, Inc. | +960.4K | $21.33M | 1.28% |
| INSM INSMED Inc | +120.7K | $12.87M | 0.769% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 5.35M | $217.37M | 12.99% | 0 | 0.0% | Unchanged | 4.96% |
| 2 | ASML Asml Holding Nv | Technology | 94.9K | $188.89M | 11.29% | 0 | 0.0% | Unchanged | 0.02% |
| 3 | COAG Hemab Therapeutics Holdings, Inc. | Healthcare | 4.18M | $153.55M | 9.18% | +4.18M | – | New | 8.95% |
| 4 | BN BROOKFIELD Corp | Financial Services | 3.50M | $149.53M | 8.94% | 0 | 0.0% | Unchanged | 0.16% |
| 5 | MPLT MapLight Therapeutics, Inc. | Healthcare | 3.69M | $132.13M | 7.9% | 0 | 0.0% | Unchanged | 8.11% |
| 6 | MIRM Mirum Pharmaceuticals, Inc. | Healthcare | 1.13M | $131.70M | 7.87% | -200.0K | -15.1% | Reduced | 1.74% |
| 7 | AVLN Avalyn Pharma Inc. | Healthcare | 3.88M | $127.84M | 7.64% | +3.88M | – | New | 8.76% |
| 8 | CRM Salesforce, Inc. | Technology | 393.2K | $61.60M | 3.68% | 0 | 0.0% | Unchanged | 0.05% |
| 9 | AVBP ArriVent BioPharma, Inc. | Healthcare | 1.50M | $52.11M | 3.12% | -442.1K | -22.8% | Reduced | 3.1% |
| 10 | ELVN Enliven Therapeutics, Inc. | Healthcare | 1.00M | $50.75M | 3.03% | -280.0K | -21.9% | Reduced | 1.37% |
| 11 | PHVS Pharvaris N.V. | Healthcare | 1.40M | $48.41M | 2.89% | -350.0K | -20.0% | Reduced | 2.37% |
| 12 | FND Floor & Decor Holdings, Inc. | Consumer Discretionary | 797.0K | $47.31M | 2.83% | +797.0K | – | New | 0.74% |
| 13 | PCVX Vaxcyte, Inc. | Healthcare | 800.0K | $46.50M | 2.78% | -60.0K | -7.0% | Reduced | 0.55% |
| 14 | FDMT 4D Molecular Therapeutics, Inc. | Healthcare | 3.25M | $43.21M | 2.58% | -401.6K | -11.0% | Reduced | 4.62% |
| 15 | VRDN Viridian Therapeutics, Inc.\DE | Healthcare | 2.14M | $39.22M | 2.34% | +135.0K | +6.8% | Added | 1.89% |
Tip. Select a row to see that position’s full history at Novo Holdings A.
As of its Q2 2026 13F filing, Novo Holdings A/S’s five largest positions were Edgewise Therapeutics, Inc. (EWTX) at 13.0%, Asml Holding Nv (ASML) at 11.3%, Hemab Therapeutics Holdings, Inc. (COAG) at 9.2%, BROOKFIELD Corp (BN) at 8.9%, MapLight Therapeutics, Inc. (MPLT) at 7.9% of the reported portfolio.
Novo Holdings A/S reported a 13F portfolio worth $1.67B across 24 positions for Q2 2026. That is up 46.7% from the previous quarter.
Its largest purchases by value were Hemab Therapeutics Holdings, Inc. ($153.55M), Avalyn Pharma Inc. ($127.84M), Floor & Decor Holdings, Inc. ($47.31M). It opened 6 new positions.
Its largest sales by value were Biomarin Pharmaceutical Inc ($37.28M), Mirum Pharmaceuticals, Inc. ($23.41M), ArriVent BioPharma, Inc. ($15.36M). It exited 2 positions entirely.
From the Form 13F-HR reports Novo Holdings A/S files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.